Insmed Q3 Revenue Surges 268% to $524.4 Million as BRINSUPRI Brings In $400.1 Million; Guidance Raised for Both Products
Insmed Incorporated (Nasdaq: INSM), the Bridgewater, New Jersey-based biopharmaceutical company, reported third-quarter results for the period ended September 30, 2026. Total revenues were $524.4 million, up 268% from $142.3 million a year earlier.
BRINSUPRI (brensocatib) generated global revenue of $400.1 million, up 29% from the second quarter, driven by strong growth in the U.S. market; the company has also launched BRINSUPRI tablets 25 mg in Japan for non-cystic fibrosis bronchiectasis. ARIKAYCE (amikacin liposome inhalation suspension) revenue was $124.4 million, up 9% year over year, driven mainly by international markets. The FDA has accepted the supplemental New Drug Application for ARIKAYCE in Mycobacterium avium complex (MAC) lung disease, granted Priority Review, and set a target action date of January 28, 2027.
Insmed reported a third-quarter net loss of $100.3 million, or $0.46 per share, sharply narrower than a net loss of $370.0 million, or $1.75 per share, a year earlier. Cost of product revenues was $78.2 million, R&D expenses $270.0 million, and SG&A expenses $253.0 million. As of September 30, the company held cash, cash equivalents and marketable securities of approximately $1.1 billion.
The company raised full-year 2026 revenue guidance for BRINSUPRI to $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion, and for ARIKAYCE to $460 million to $470 million, from $450 million to $470 million. Chair and CEO Will Lewis said the quarter was defined by commercial momentum, regulatory achievements and advancement across the diversified pipeline, with BRINSUPRI's U.S. launch continuing to exceed expectations.
Source: GSM · USA (original Chinese edition)
Photo: 图：实验室研究实景（资料图）。Yakuzakorat摄，CC BY-SA 4.0，经Wikimedia Commons。 / Laboratory research (file photo). Photo by Yakuzakorat, CC BY-SA 4.0, via Wikimedia Commons.
